Cargando…
Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Masson SAS.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259019/ https://www.ncbi.nlm.nih.gov/pubmed/35809859 http://dx.doi.org/10.1016/j.idnow.2022.06.007 |
| _version_ | 1784741679573499904 |
|---|---|
| author | Salvagno, G.L. Henry, B.M. Lippi, G. |
| author_facet | Salvagno, G.L. Henry, B.M. Lippi, G. |
| author_sort | Salvagno, G.L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9259019 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Masson SAS. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92590192022-07-07 Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster Salvagno, G.L. Henry, B.M. Lippi, G. Infect Dis Now Letter to the Editor Elsevier Masson SAS. 2022-09 2022-07-06 /pmc/articles/PMC9259019/ /pubmed/35809859 http://dx.doi.org/10.1016/j.idnow.2022.06.007 Text en © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Salvagno, G.L. Henry, B.M. Lippi, G. Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster |
| title | Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster |
| title_full | Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster |
| title_fullStr | Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster |
| title_full_unstemmed | Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster |
| title_short | Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster |
| title_sort | anti-sars-cov-2 igg antibodies in patients with or without sars-cov-2 infection after bnt162b2 vaccine booster |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259019/ https://www.ncbi.nlm.nih.gov/pubmed/35809859 http://dx.doi.org/10.1016/j.idnow.2022.06.007 |
| work_keys_str_mv | AT salvagnogl antisarscov2iggantibodiesinpatientswithorwithoutsarscov2infectionafterbnt162b2vaccinebooster AT henrybm antisarscov2iggantibodiesinpatientswithorwithoutsarscov2infectionafterbnt162b2vaccinebooster AT lippig antisarscov2iggantibodiesinpatientswithorwithoutsarscov2infectionafterbnt162b2vaccinebooster |